Middle East Respiratory Syndrome Coronavirus
"Middle East Respiratory Syndrome Coronavirus" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A coronavirus first reported in the summer of 2012 in a pneumonia patient in SAUDI ARABIA. It is related to SARS VIRUS. MERS-CoV has an estimated incubation period of 12 days and symptoms include renal failure and severe acute pneumonia with often fatal outcome.
| Descriptor ID |
D065207
|
| MeSH Number(s) |
B04.820.504.540.150.113.750
|
| Concept/Terms |
Middle East Respiratory Syndrome Coronavirus- Middle East Respiratory Syndrome Coronavirus
- MERS-CoV
- MERS Virus
- MERS Viruses
- Virus, MERS
- Viruses, MERS
- Middle East respiratory syndrome-related coronavirus
- Middle East respiratory syndrome related coronavirus
|
Below are MeSH descriptors whose meaning is more general than "Middle East Respiratory Syndrome Coronavirus".
Below are MeSH descriptors whose meaning is more specific than "Middle East Respiratory Syndrome Coronavirus".
This graph shows the total number of publications written about "Middle East Respiratory Syndrome Coronavirus" by people in this website by year, and whether "Middle East Respiratory Syndrome Coronavirus" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2013 | 3 | 0 | 3 |
| 2014 | 90 | 6 | 96 |
| 2015 | 113 | 16 | 129 |
| 2016 | 122 | 21 | 143 |
| 2017 | 74 | 16 | 90 |
| 2018 | 70 | 13 | 83 |
| 2019 | 81 | 16 | 97 |
| 2020 | 80 | 98 | 178 |
| 2021 | 45 | 22 | 67 |
To return to the timeline, click here.
Below are the most recent publications written about "Middle East Respiratory Syndrome Coronavirus" by people in Profiles.
-
Anti-Coronavirus Vaccines: Past Investigations on SARS-CoV-1 and MERS-CoV, the Approved Vaccines from BioNTech/Pfizer, Moderna, Oxford/AstraZeneca and others under Development Against SARSCoV- 2 Infection. Curr Med Chem. 2022; 29(1):4-18.
-
Statistical optimization of bile salt deployed nanovesicles as a potential platform for oral delivery of piperine: accentuated antiviral and anti-inflammatory activity in MERS-CoV challenged mice. Drug Deliv. 2021 Dec; 28(1):1150-1165.
-
A comparative recombination analysis of human coronaviruses and implications for the SARS-CoV-2 pandemic. Sci Rep. 2021 08 30; 11(1):17365.
-
Multiyear prospective cohort study to evaluate the risk potential of MERS-CoV infection among Malaysian Hajj pilgrims (MERCURIAL): a study protocol. BMJ Open. 2021 08 26; 11(8):e050901.
-
Seroprevalence of SARS-CoV-2 among high-risk healthcare workers in a MERS-CoV endemic area. J Infect Public Health. 2021 Sep; 14(9):1268-1273.
-
A Novel Frameshifting Inhibitor Having Antiviral Activity against Zoonotic Coronaviruses. Viruses. 2021 08 18; 13(8).
-
Pharmacophore-Based Virtual Screening, Quantum Mechanics Calculations, and Molecular Dynamics Simulation Approaches Identified Potential Natural Antiviral Drug Candidates against MERS-CoV S1-NTD. Molecules. 2021 Aug 17; 26(16).
-
What Binds Cationic Photosensitizers Better: Brownian Dynamics Reveals Key Interaction Sites on Spike Proteins of SARS-CoV, MERS-CoV, and SARS-CoV-2. Viruses. 2021 08 15; 13(8).
-
Coronavirus Pseudotypes for All Circulating Human Coronaviruses for Quantification of Cross-Neutralizing Antibody Responses. Viruses. 2021 08 10; 13(8).
-
Direct Comparison of N-Glycans and Their Isomers Derived from Spike Glycoprotein 1 of MERS-CoV, SARS-CoV-1, and SARS-CoV-2. J Proteome Res. 2021 09 03; 20(9):4357-4365.